Article
Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 May 2017
Dréno B, Ribas A, Larkin J, Ascierto P A, Hauschild A, Thomas L, Grob J-J, Koralek D O, Rooney I, Hsu J J, McKenna E F, McArthur G A
Abstract excerpt
Background: In the coBRIM phase III trial, the addition of cobimetinib, an MEK inhibitor, to vemurafenib, a BRAF inhibitor, significantly improved progression-free survival [hazard ratio (HR), 0.58; P < 0.0001] and overall survival (HR, 0.70; P = 0.005) in advanced BRAF-mutated melanoma. Here, we report on the incidence, course, and management of key adverse events (AEs) in the coBRIM study. Patients and methods:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.